The combination of insider selling and a recent equity offering warrants close monitoring of further insider activity and upcoming clinical catalysts. The positive regulatory news for AMT-130 may support the stock, but the insider sales suggest caution near term. Watch for additional Form 4 filings and any updates on the BLA submission timeline.
Price Chart
Executive Summary
uniQure's CEO and CMO sold ~$2.9M in open-market sales within days of a $225M public offering. The sales are modest relative to market cap (0.1%) but notable given the insider seniority and the proximity to the capital raise. The company recently announced FDA alignment for accelerated approval of its lead gene therapy, which tempers the bearish signal.
Key Financial Metrics
Key Facts
- CEO Matthew Kapusta sold 28,700 shares at $50.02 for ~$1.44M on June 25, 2026.
- CMO Walid Abi-Saab sold a total of ~31,434 shares across three trades (June 26 & 30) for ~$1.46M.
- The insider selling cluster follows a $225M underwritten public offering priced at $45.50/share on June 23-24.
- uniQure recently received FDA alignment to use Phase I/II data as primary basis for a BLA submission under accelerated approval for AMT-130.
- Total insider sales represent approximately 0.1% of uniQure's $2.8B market cap.
Financial Impact
CEO and CMO sold ~$2.9M in open-market sales, representing ~0.1% of market cap.
Risk Factors
- Further insider selling could signal lack of confidence.
- Dilution from the $225M offering may pressure the stock.
- Execution risk for AMT-130 BLA submission and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1783026103175 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access